ArcticZymes Technologies — Director's Dealing 2018

Mar 19, 2018

Biotec Pharmacon - Mandatory notification of trade

Biotec Pharmacon - Mandatory notification of trade

(Tromsø 19. March 2018) Rolf E. Engstad, CSO of Biotec BetaGlucans has on

16. March purchased 20 000 shares in Biotec Pharmacon at NOK 6.70 per share.

After this transaction holds Engstad 390.774 shares and 80.000 options in Biotec

Pharmacon

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

For further information, please contact

Børge Sørvoll

CFO

+47 952 90 187

borge.sorvoll@biotec.no